Koch Disruptive Technologies (KDT) marked its founding more than two years ago with an investment that has made a significant impact.
Its first partner: a commercial-stage medical device company, INSIGHTEC, whose incisionless treatment option, Exablate Neuro, delivers focused ultrasound waves to treat essential tremor and tremor-dominant Parkinson's disease patients.
“They've treated now close to 3,000 essential tremor and Parkinson's tremor-dominant patients in just those two years. They've expanded their talent and capabilities immensely. There's exploding interest for their technology from hospitals, from universities, and they're now commercial in 22 countries with an R&D pipeline that has tremendous potential,” KDT President Chase Koch said in a wide-ranging interview with the Focused Ultrasound Foundation’s Founder and Chairman Neal F. Kassell, MD.
Making that sort of impact is what drove KDT’s creation, Koch explained, with Koch companies working as a real-time laboratory to help scale innovations.
“We started Koch Disruptive Technologies that really our main role for Koch Industries is to originate these disruptive and transformative founders and companies, invest in them, and then connect them into Koch,” he said.
Koch also discussed how these partnerships will help transform lives and help even more people do the same for others.
“There are so many different disease states that can be treated with this, that's one of the main reasons we're so excited, and we're excited about INSIGHTEC and their leadership in this space. If they can do well, then that's going to inspire others to innovate and spawn a lot of different technology to help transform this space and help so many patients,” Koch said.
Read the transcript of their discussion here.
Listen to the full discussion below.